3 May 2022 Affini-T Therapeutics’ KRAS TCR T Cell Therapy Program to be Presented at the Annual Meeting of the American Society of Gene and Cell Therapy read more
8 April 2022 Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022 read more
5 April 2022 Affini-T Expands Board of Directors with Appointments of Michael Varney, Ph.D., and Daniel Faga read more
4 April 2022 Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. To Its Board Of Directors read more
22 March 2022 Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations read more
